ahlam1399
10-04-2016, 12:35 PM
UPDATE 2-AstraZeneca cuts Brilinta sales hopes on artery disease failure
* Drugmaker sells rights to Toprol-XL for up to $223 mln (Adds executive interview, latest shares)http://feeds.feedburner.com/~ff/reuters/companyNews?d=yIl2AUoC8zA (http://feeds.reuters.com/~ff/reuters/companyNews?a=-hDXQuD7oI4:WBOKn2EuzqA:yIl2AUoC8zA) http://feeds.feedburner.com/~ff/reuters/companyNews?i=-hDXQuD7oI4:WBOKn2EuzqA:V_sGLiPBpWU (http://feeds.reuters.com/~ff/reuters/companyNews?a=-hDXQuD7oI4:WBOKn2EuzqA:V_sGLiPBpWU) http://feeds.feedburner.com/~ff/reuters/companyNews?i=-hDXQuD7oI4:WBOKn2EuzqA:F7zBnMyn0Lo (http://feeds.reuters.com/~ff/reuters/companyNews?a=-hDXQuD7oI4:WBOKn2EuzqA:F7zBnMyn0Lo)
http://feeds.feedburner.com/~r/reuters/companyNews/~4/-hDXQuD7oI4
* Drugmaker sells rights to Toprol-XL for up to $223 mln (Adds executive interview, latest shares)http://feeds.feedburner.com/~ff/reuters/companyNews?d=yIl2AUoC8zA (http://feeds.reuters.com/~ff/reuters/companyNews?a=-hDXQuD7oI4:WBOKn2EuzqA:yIl2AUoC8zA) http://feeds.feedburner.com/~ff/reuters/companyNews?i=-hDXQuD7oI4:WBOKn2EuzqA:V_sGLiPBpWU (http://feeds.reuters.com/~ff/reuters/companyNews?a=-hDXQuD7oI4:WBOKn2EuzqA:V_sGLiPBpWU) http://feeds.feedburner.com/~ff/reuters/companyNews?i=-hDXQuD7oI4:WBOKn2EuzqA:F7zBnMyn0Lo (http://feeds.reuters.com/~ff/reuters/companyNews?a=-hDXQuD7oI4:WBOKn2EuzqA:F7zBnMyn0Lo)
http://feeds.feedburner.com/~r/reuters/companyNews/~4/-hDXQuD7oI4